When: Confirmed daily close above $145 with volume >7M shares

Then: Add to position

BUY

• RSI moved from 49 to 62 in one week—12-point acceleration in 5 trading days creates momentum burnout risk
• Upper Bollinger Band entry at $138 is a stretched risk-reward; the $134-135 add zone offers better value
• The $12.6B write-down is management's own admission of prior overvaluation, raising questions about the $11.2B acquisition underwriting
• Trodelvy Phase III combo failure with Merck is a credibility hit to the oncology pipeline beyond a $50M optionality loss
• PrEP $1B quarterly revenue (doubling YoY) is already in the price after the rally from low-120s to $138
• Net debt jumped 60% from $14.5B to $23B in one quarter—223% D/E creates leverage risk if acquisition underperforms
• Social sentiment silence is a data gap; the bullish institutional accumulation narrative is speculative
• Entry plan: one-third at $138, add at $134-135 on pullback, add on confirmed breakout above $145 with volume
• $129.50 is the hard stop level; $130-131 is the support zone
• Dividend yield of 2.4% is part of the bull case and could be sacrificed if M&A fails to deliver

→ vs aggressive: Aggressive analyst quotes RSI at 61.81 without acknowledging the velocity of the 12-point move in 5 days—this momentum burn risk is being ignored

→ vs aggressive: Aggressive analyst dismisses the $12.6B write-down as non-cash accounting noise, but it represents real capital allocation failures that question management credibility

→ vs aggressive: Aggressive analyst frames Trodelvy failure as $50M lost optionality; conservative view is it's a pattern/credibility hit to pipeline execution

→ vs aggressive: Aggressive analyst says PrEP is the counterweight, but PrEP is already in the price after the 6-week rally from 120s to 138

→ vs aggressive: Aggressive analyst says 223% D/E is fine because FCF is $10B, but $23B net debt jumped 60% in one quarter and rating agencies could start a downgrade cycle

→ vs aggressive: Aggressive analyst invents bullish explanation (institutional accumulation) for missing social sentiment data; conservative view is it's genuinely unknown

→ vs aggressive: Aggressive analyst tries to convince the trader to size up; conservative position is to reinforce the one-third phased entry discipline, not override it

→ vs neutral: Neutral analyst flagged social sentiment as low confidence data gap; aggressive analyst incorrectly converts this into a bullish narrative

BUY

• Affirm BUY at current proposal with one-third phased entry
• Hard stop at $129.50
• Add zones at 134-135 and above 145 with volume confirmation
• RSI moved from 49 to 62 in one week (12-point jump in 5 sessions) indicating momentum velocity concern
• Middle Bollinger Band at 132.62 suggests roughly 4% drawdown potential from entry at 138
• Entry at 138 versus add zone of 134-135 is 3-4% cost basis difference
• $12B IPR&D write-down reflects information about management underwriting discipline
• Net debt increased from $14.5B to $23B in one quarter
• Trodelvy-Keytruda failure is a real but bounded concern, not a thesis-breaker
• Low-confidence mildly bullish sentiment should reduce position size rather than dictate direction
• Fundamentals justify position; technicals justify phased entry; integration and leverage risks justify disciplined sizing

→ vs aggressive: RSI argument is incomplete—quoting static 62 level ignores 12-point weekly velocity; momentum regimes with that kind of velocity either continue with shallow pullback or mean revert hard with no upper bound protection

→ vs aggressive: Bollinger Band touch treated as continuation signal without acknowledging asymmetric downside if it fails

→ vs aggressive: $50-100M Trodelvy impact estimate is too clean and minimizes real oncology pipeline credibility hit

→ vs aggressive: Inventing bullish explanation for missing social sentiment data is a leap

→ vs conservative: Leverage argument is fair in principle but overweighted—applying static credit framework to company with $10B annual FCF and 0.336 beta

→ vs conservative: Wanting to wait entirely for pullback ignores the plan already addresses entry concern through sizing; may miss breakout above 145

→ vs conservative: Implying Trodelvy failure is a thesis-breaker is wrong—it is incremental to HIV and PrEP franchises

→ vs conservative: Being cautious because retail is quiet is also a leap; honest answer is low-confidence uncertainty